Denali Therapeutics Inc.
04/18/2024 | Press release | Distributed by Public on 04/18/2024 14:04
Additional Proxy Soliciting Materials - Form DEFA14A
Document
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
________________________________________
SCHEDULE 14A
PROXY STATEMENT PURSUANT TO SECTION 14(a) OF THE
SECURITIES EXCHANGE ACT OF 1934
SECURITIES EXCHANGE ACT OF 1934
________________________________________
Filed by the Registrant x
Filed by a Party other than the Registrant ¨
Check the appropriate box:
| ¨ |
Preliminary Proxy Statement
|
| ¨ |
Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2))
|
| ¨ |
Definitive Proxy Statement
|
| x |
Definitive Additional Materials
|
| ¨ | Soliciting Material Pursuant to §240.14a-12 |
Denali Therapeutics Inc.
(Name of Registrant as Specified In Its Charter)
Payment of Filing Fee (Check the appropriate box):
|
x
|
No fee required |
| ¨ | Fee paid previously with preliminary materials |
| ¨ | Fee computed on table in exhibit required by Item 25(b) per Exchange Act Rules 14a-6(i)(1) and 0-11 |